Industry Newspeptide therapeuticsai enabled designphysics based simulationimmunology
Pinnacle Medicines Raises $89M Series B
7.1
Relevance Score
Pinnacle Medicines today announced the closing of an oversubscribed $89 million Series B financing co-led by LAV and Foresite Capital, with participation from Quan Capital, Hankang Capital, RA Capital, Logos Capital and OrbiMed. The Doylestown, PA biotech uses integrated physics-based molecular simulations, AI-enabled design and advanced peptide chemistry to develop oral peptide therapeutics and will advance programs in immunology and cardiometabolic diseases.
Scoring Rationale
Strong Series B funding and AI-physics platform demonstrate potential, limited by single-company announcement and limited technical details.
Free Career Roadmaps8 PATHS
Step-by-step roadmaps from zero to job-ready — curated courses, salary data, and the exact learning order that gets you hired.
Data Analyst
Explore all career paths $95K
Data Scientist$130K
ML Engineer$155K
AI Engineer$160K
Data Engineer$140K
Analytics Eng.$140K
MLOps Engineer$160K
Quant Analyst$175K
Sources
- Read OriginalPinnacle Medicines Raises $89M Series Bvcnewsdaily.com
